JAZZ vs SI · P/E 1988, rev $4.07B vs rev $11.8M
Jazz Pharmaceuticals PLC (JAZZ) versus Shoulder Innovations, Inc. (SI) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Shoulder Innovations, Inc. (SI) common stock listed on NYSE.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported SI revenue for 2025-09-30 was $11.8M. Net income was -$8.7M. Revenue was up 6.7% from 2025-06-30 to 2025-09-30. SI currently screens at market cap $369.7M.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. SI currently screens at market cap $369.7M.
Not investment advice. Open the JAZZ and SI stock pages for the full models.
Not investment advice.